Table 2 Levels of comorbidities, mortality risk (Charlson score), and use of medication and medical healthcare in the whole study population and in patients across the three practices studied.
| Characteristic | All (n = 300) | GP (n = 100) | DNS (n = 100) | MS (n = 100) | p Value for trend |
|---|---|---|---|---|---|
| Lifetime comorbidities per person (No) | |||||
| Total | 7.0 (0.2) | 5.7 (0.3) | 6.5 (0.3) | 8.7 (0.4) | <0.001 |
| Complicating | 5.0 (0.2) | 3.6 (0.3) | 4.7 (0.3) | 6.7 (0.3) | <0.001 |
| Concurrent | 2.0 (0.1) | 2.1 (0.2) | 1.8 (0.2) | 2.0 (0.2) | 0.799 |
| Mortality risk (Charlson Index score) | 4.5 (0.1) | 3.9 (0.2) | 4.4 (0.2) | 5.3 (0.2) | <0.001 |
| Medication use (No) | |||||
| Total | 6.6 (0.2) | 6.3 (0.3) | 6.6 (0.3) | 7.0 (0.3) | 0.125 |
| Diabetes‐related | 5.0 (0.1) | 4.6 (0.2) | 5.1 (0.2) | 5.5 (0.3) | 0.017 |
| Medical healthcare use (No) | |||||
| Specialties involved | 4.0 (0.1) | 3.3 (0.2) | 3.8 (0.2) | 4.9 (0.2) | <0.001 |
| Consultations | 17.1 (1.1) | 9.8 (1.3) | 13.2 (1.1) | 38.4 (1.1) | <0.001 |
GP, general practice; DNS, diabetes nurse specialist practice; MS medical specialist practice
Data are mean (SE); all analyses were adjusted for age, sex and HbA1c.